OKYO Pharma Ltd (OKYO) CEO purchases 15,000 common shares at $1.539
Rhea-AI Filing Summary
OKYO Pharma Ltd reported that Chief Executive Officer Robert John Dempsey purchased 15,000 shares of common stock on July 22, 2026 at $1.539 per share in a transaction coded as a purchase in an open market or private transaction. Following this trade, he directly holds 15,000 shares. The Form 4/A states it amends the July 23, 2026 filing solely to correct the transaction code, with no other transactions affected and the Rule 10b5-1 trading-plan box left unchecked.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 15,000 shares
Net Buy
1 txn
Insider
Dempsey Robert John
Role
CHIEF EXECUTIVE OFFICER
Bought
15,000 shs ($23K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | COMMON STOCK | 15,000 | $1.539 | $23K |
Holdings After Transaction:
COMMON STOCK — 15,000 shares (Direct)
Key Figures
Shares purchased: 15,000 shares
Purchase price: $1.539 per share
Shares owned after transaction: 15,000 shares
+1 more
4 metrics
Shares purchased
15,000 shares
Non-derivative common stock purchase on July 22, 2026
Purchase price
$1.539 per share
Price per share for the 15,000-share common stock purchase
Shares owned after transaction
15,000 shares
Direct common stock holdings reported following the purchase
Net buy shares
15,000 shares
Net buy direction from transaction summary for this filing
Key Terms
Form 4/A, open market or private transaction, non-derivative, Rule 10b5-1
4 terms
Form 4/A regulatory
"This Form 4/A amends the Form 4 filed on July 23, 2026"
Form 4/A is an amended filing that corrects or updates an earlier Form 4, the mandatory report that insiders (like company executives, directors, or large shareholders) must file when their ownership stakes change. Think of it as an edited receipt showing who bought or sold stock and when; investors use it to track insider confidence, detect potential conflicts, and spot trading patterns that might signal future company prospects.
open market or private transaction financial
"Purchase in open market or private transaction"
non-derivative financial
"transaction_type: "non-derivative""
Rule 10b5-1 regulatory
"aff_10b5_one is the filing's document-level Rule 10b5-1 checkbox"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did OKYO report in this Form 4/A?
OKYO reported that CEO Robert John Dempsey purchased 15,000 shares of common stock on July 22, 2026 at $1.539 per share. The trade is classified as a purchase in an open market or private transaction and is held directly.
Who is the insider involved in the latest OKYO (OKYO) filing?
The insider is Robert John Dempsey, Chief Executive Officer and director of OKYO Pharma Ltd. He reported a direct purchase of 15,000 common shares on July 22, 2026, bringing his reported direct holdings to 15,000 shares after the transaction.
What change does this Form 4/A amendment make for OKYO (OKYO)?
The Form 4/A only corrects the transaction code for the July 22, 2026 purchase. It states that this amendment is solely to fix that code, with no other transactions or amounts from the prior Form 4 affected or revised.